On November 12, 2026, the Center for Medical Device Evaluation (CMDE) of China's National Medical Products Administration published a notice dated November 10, 2026 that opens a public consultation on 10 draft technical review points for Class II in vitro diagnostic reagent medical devices, led by the phosphorus determination reagent points (磷测定试剂技术审评要点(征求意见稿)). The notice is 关于公开征求《磷测定试剂技术审评要点(征求意见稿)》等10项第二类体外诊断试剂医疗器械技术审评要点意见的通知, and it attaches the drafts, a feedback form and a contact list.

China manufacturers of Class II phosphorus determination reagents, China manufacturers of the other Class II IVD reagents in this CMDE batch of 10 technical review points, overseas IVD companies registering those Class II reagents for the China market, and China registration agents filing Class II IVD dossiers with provincial medical products administrations must submit the CMDE opinion feedback form by December 15, 2026 and check pending Class II IVD registration dossiers, including phosphorus determination reagents, against the draft technical review points, or comments received after December 15, 2026 fall outside this consultation and do not shape the technical review points CMDE will apply to these Class II IVD registration dossiers.

What is in the November 2026 CMDE consultation?

Technical review points are the draft documents the Center for Medical Device Evaluation compiled for the technical review of Class II in vitro diagnostic reagent medical devices and published for public comment.

CMDE compiled the 10 drafts, after research and discussion, to support the formulation and revision of medical device technical review points, and opened them for comment from the day of the notice. The notice title names only the phosphorus determination reagent points (征求意见稿). The other nine items sit in the Annex 1 archive and are not named on the notice page. The official text is the CMDE notice of November 12, 2026. The drafts are the Annex 1 archive.

StepDateWhat the notice states
Notice signedNovember 10, 2026CMDE, under the National Medical Products Administration
PublishedNovember 12, 2026Posted on the CMDE work-updates page
Comments dueDecember 15, 2026Feedback form to the contacts in Annex 3, before that date

Who has to act on these Class II IVD drafts, and by when?

Manufacturers in China of Class II phosphorus determination reagents and of the other Class II IVD reagents in this batch of 10, overseas IVD companies registering those reagents for the China market, and China registration agents filing Class II IVD dossiers with provincial medical products administrations are the actors the comment window hits.

Under State Council Order No. 739, Class II devices follow provincial registration and CMDE carries out the technical evaluation. The notice asks any unit with comments to send the Annex 2 form to the Annex 3 contact before December 15, 2026. It sets no application date, transition or fee.

Across the Life Sciences and MedTech industry in China, Obsidian tracks 15 regulatory texts in force, amended or in preparation, as of November 2026.

What should a pending Class II dossier check before December 15, 2026?

Open Annex 1, match each of the 10 drafts to a live or planned Class II registration, and compare the points with the product technical requirements, performance studies and clinical evaluation already in the dossier. Where a draft asks for a study, a specimen type, a measuring range, a reference interval or a labelling statement the dossier does not carry, send a written comment before December 15, 2026 on the Annex 2 opinion feedback workbook to the contact in the Annex 3 contact list, and keep a copy. A provincial medical products administration is not told to apply the drafts before CMDE adopts them.

  • Download Annex 1 and list which of the 10 drafts cover reagents you manufacture, import or register in China.
  • Match each hit to the Class II dossier, including phosphorus determination reagents, that is pending or about to be filed.
  • Note every draft requirement the dossier does not meet, with the section of the draft.
  • File the Annex 2 form with the Annex 3 contact before December 15, 2026, and keep the submission record.

Continuous per-jurisdiction monitoring surfaces a CMDE consultation on the day the notice is posted, while the comment window is still open.

What happens if a comment misses December 15, 2026?

Comments received after December 15, 2026 fall outside this consultation and do not shape the technical review points CMDE will apply to these Class II IVD registration dossiers.

The notice states no fine and no refusal of a registration for a company that stays silent. A view that arrives after December 15, 2026 is outside the window opened on November 12, 2026. The notice does not date the adopted points and does not announce a second consultation. A dossier built to an older review practice can still be queried once the points are final, so the Annex 1 comparison belongs in the same window as the comment.

Live
China NMPA medical devices: Order 739 implementation, registration and clinical evaluation rules
Monitor Chinese medical device regulation for the life sciences and medtech industry, for Swiss manufacturers registering devices in China.
Email 30+ news

Before December 15, 2026, confirm whether any of the 10 drafts covers a Class II IVD you place on the China market, compare it with the pending dossier, send the Annex 2 form to the Annex 3 contact, and record that the points are still drafts. Obsidian keeps this consultation beside the China medical device register, so the adopted text is read against the same reagents when CMDE issues it.